Fundz

Axogen

Biotechnology, Health Care, Medical · 483 employees

Axogen is a medical technology company focused on the science, development, and commercialization of innovative solutions for peripheral nerve repair, with a mission to make nerve repair the expected standard of care. Through ongoing research, education, and close collaboration with surgeons and healthcare providers worldwide, Axogen advances clinical outcomes in nerve injury treatment. Its portfo

Funding history

  • Funding Round — $124.0M — Jan 2026

Recent signals

  • Feb 24, 2026: SEC 8-K (2.02): On February 24, 2026, Axogen, Inc. announced its financial results for the fourth quarter of 2025, highlighting relevant metrics such as revenue and net income. This report is significant for investors as it provides an update on the company's financial health and operational performance. The press release is included as Exhibit 99.1 and is important for stakeholders assessing the company's progress and future prospects. The announcement reflects the company’s performance over the past quarter and may influence stock market reactions and investor decisions.
  • Jan 23, 2026: Raised $124.0M
  • Jan 21, 2026: SEC 8-K (1.01): On January 21, 2026, Axogen, Inc. entered into a Material Definitive Agreement through an Underwriting Agreement with Wells Fargo Securities, LLC and Mizuho Securities USA LLC. The Company agreed to sell 4,000,000 shares of its common stock at a public offering price of $31.00 each. Additionally, the Underwriters have a 30-day option to purchase up to an extra 600,000 shares. This capital raise is part of an anticipated funding strategy to enhance Axogen's operational capabilities and support future growth initiatives.
  • Dec 03, 2025: SEC 8-K (2.01): On December 3, 2025, Axogen, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its Biologics License Application for Avance®, an acellular nerve allograft. This approval is a significant regulatory milestone for Axogen as it enables the commercialization of Avance® for clinical use in reconstructive surgery. The strategic implications include increased market access and potential revenue growth for Axogen in the healthcare sector, emphasizing its role in nerve repair solutions. This event directly impacts the company's operations and market position as they move forward with the product launch.
  • May 08, 2025: Axogen Appoints Lindsey Hartley as Chief Financial Officer
  • Jan 12, 2025: Axogen Appoints Craig Swandal as Vice President of Operations
  • Aug 09, 2024: Axogen Appoints Michael Dale as CEO to Replace Karen Zaderej

See plans & pricing → Track Axogen’s funding, hiring, and signals — with verified contacts — on Fundz.